Strata Skin Sciences (SSKN) to Announce Earnings on Wednesday

Strata Skin Sciences (NASDAQ:SSKN) is projected to release its Q1 2026 results after the market closes on Wednesday, August 19th. Analysts expect Strata Skin Sciences to post earnings of ($0.43) per share and revenue of $5.53 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Strata Skin Sciences Stock Down 98.2%

Shares of Strata Skin Sciences stock opened at $0.00 on Wednesday. The business has a fifty day simple moving average of $0.07 and a 200 day simple moving average of $0.28. The stock has a market cap of $588.80, a PE ratio of -0.00 and a beta of -0.05. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 10.22. Strata Skin Sciences has a 12 month low of $0.00 and a 12 month high of $3.86.

Hedge Funds Weigh In On Strata Skin Sciences

A hedge fund recently bought a new position in Strata Skin Sciences stock. Susquehanna International Group LLP bought a new position in shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.24% of Strata Skin Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 32.43% of the company’s stock.

Strata Skin Sciences Company Profile

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.